Boston Scientific anticipates Q4 2026 organic revenue down 3% to down 1% and adjusted EPS $0.77-$0.79 amid cyber and EP/

Boston Scientific Q3 2026 earnings: cyberattack, EP share pressure, and weak Q4 guidance cloud 2027 outlook.